TABLE 4.
Physician-assessed response and treatment duration in patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) according to subgroups based on Eastern Cooperative Oncology Group (ECOG) performance status and presence of brain metastases
| Radiological tumour evaluation | ECOG performance status | Brain metastases | ||
| 0–1 (n=134) | 2–4 (n=51) | Present (n=97) | Absent (n=64) | |
| Assessed response | ||||
| Evaluable subjects | 109 | 33 | 72 | 50 |
| CR | 8 (7.3) | 0 (0.0) | 2 (2.8) | 4 (8.0) |
| PR | 52 (47.7) | 14 (42.4) | 33 (45.8) | 26 (52.0) |
| SD | 28 (25.7) | 4 (12.1) | 18 (25.0) | 6 (12.0) |
| PD | 11 (10.1) | 8 (24.2) | 8 (11.1) | 8 (16.0) |
| Not realised | 9 (8.3) | 6 (18.2) | 10 (13.9) | 5 (10.0) |
| Not evaluable | 1 (0.9) | 1 (3.0) | 1 (1.4) | 1 (2.0) |
| ORR | 60 (55.0) | 14 (42.4) | 35 (48.6) | 30 (60.0) |
| Treatment duration | ||||
| Subjects | 131 | 43 | 92 | 60 |
| Duration months | 4.6 (0.4–22.4) | 2.3 (0.4–19.9) | 3.3 (0.4–23.0) | 4.5 (0.4–22.2) |
Data are presented as n, n (%) or median (range) unless otherwise stated. CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; ORR: overall response rate.